ArticleEuropean urology2020
Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
Article in European urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Cribriform and intraductal carcinoma in prostate cancer - implications for risk stratification and therapeutic decision-making.Nature reviews. Urology · 2026Review
- Predictive value of baseline risk factors and early prostate-specific antigen (PSA) kinetics for achieving deep PSA decline in metastatic hormone-sensitive prostate cancer: implications for treatment intensification.Translational cancer research · 2026Article
- Impact of positive surgical margins on biochemical recurrence and metastases after radical prostatectomy.BJU international · 2026Article
- MRI radiomics predicting cribriform growth informs active surveillance decision in intermediate-risk prostate cancer.European radiology experimental · 2026Article
- The evolution of prostate cancer grading: from Gleason score to risk taxonomy and the artificial intelligence revolution.Virchows Archiv : an international journal of pathology · 2026Review
- Correlation of unfavourable and favourable histology at radical prostatectomy with Decipher scores and freedom from biochemical recurrence.Histopathology · 2026Article
- Intraductal carcinoma of the prostate: A comprehensive literature review focused on grading challenges and controversies.Histology and histopathology · 2025Review
- Current grading of prostate cancer.Pathologie (Heidelberg, Germany) · 2025Review
- Classification of prostatic adenocarcinoma as favourable/unfavourable histology has high interobserver agreement in prostate needle core biopsies.Histopathology · 2025Article
- Beyond Gleason grading: MRI radiomics to differentiate cribriform growth from non-cribriform growth in prostate cancer men.Magma (New York, N.Y.) · 2025Article
- [Current grading of prostate cancer. German version].Pathologie (Heidelberg, Germany) · 2025Review
- High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trial.Virchows Archiv : an international journal of pathology · 2025Article
- Histopathological evaluation and grading for prostate cancer: current issues and crucial aspects.Asian journal of andrology · 2024Review
- Article
- GRIN3A: A biomarker associated with a cribriform pattern and poor prognosis in prostate cancer.Neoplasia (New York, N.Y.) · 2024Article
- Metabolic imaging across scales reveals distinct prostate cancer phenotypes.Nature communications · 2024Article
- Review
- Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?The Prostate · 2023Article
- Review
- The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates.Prostate cancer and prostatic diseases · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrade groups (GGs) are an important parameter for therapeutic decision making in prostate cancer (Pca) patients. Invasive cribriform and/or intraductal carcinoma (CR/IDC) has an independent prognostic value for disease outcome, but are not included in the GG limiting their clinical use.
objectiveTo perform a proof-of-principle study incorporating CR/IDC in the current GG. DESIGN, SETTING, AND
participantsAll prostate biopsies of 1031 men with screen-detected Pca between 1993 and 2000 were reviewed for the current GG (ranging from 1 to 5) and CR/IDC. The cribriform grade (cGrade) was equal to the GG if CR/IDC was present and GG minus 1 if not. GG1 was cGrade1 if intraductal carcinoma was absent.
interventionBiopsy review for GG and CR/IDC. A total of 406 patients had received radical prostatectomy (RP), 508 radiotherapy (RT), 108 surveillance, and eight hormonal therapy, and the treatment was unknown for one patient. Outcome measurements and statistical analysis disease-specific survival (DSS), metastasis-free survival (MFS), and biochemical recurrence-free survival (BCRFS) after 15.1 yr (interquartile range 10.9-19.7 yr) follow-up were compared using Harrell's C-statistic. RESULTS AND LIMITATIONS: The biopsy GGs were 486 GG1, 310 GG2, 104 GG3, 64 GG4, and 67 GG5; cGrade distributions were 738 cGrade1, 102 cGrade2, 91 cGrade3, 58 cGrade4, and 42 cGrade5. The cGrade had a better discriminative value than the GG for DSS (C-index 0.79; 95% confidence interval 0.74-0.83 vs 0.76; 0.71-0.82) and MFS (0.79; 0.74-0.84 vs 0.77; 0.72-0.82). The discriminative value for BCRFS after RP and RT was similar for both models. Different diagnostic, such as use of sextant biopsies, and therapeutic strategies in the 1990s are the limitations of this study.
conclusionsThe cGrade is a simple Pca grade modification with better discriminative values for DSS and MFS than the GG, particularly impacting decision making in men with current GG2 Pca. PATIENT SUMMARY: Microscopic grading is an important factor for decision making in prostate cancer (Pca) patients. We show that a simple grade modification better predicts Pca outcome and might improve treatment choices.
Indexed as
Identifiers
31439369What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.